Abstract
The recent authorisation of vaccines against the novel coronavirus, SARS-CoV-2, raises important questions about prioritising the vaccine to those who are most likely to benefit from protection. Unlike influenza vaccines,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Archives of disease in childhood. Fetal and neonatal edition
Paper Title
Journal
Date
